Designing a peptide-oligonucleotide conjugate is rarely just a matter of combining one peptide sequence with one nucleic acid sequence. Researchers may already know the peptide motif, the antisense strand, the siRNA sequence, the PMO, the PNA, or the assay probe they want to use, yet still face a difficult practical question: what linker should connect the two components? The answer affects conjugation efficiency, purification behavior, analytical interpretation, storage stability, cellular uptake, target binding, and the final biological readout.
Linker selection is especially important because peptides and oligonucleotides bring very different chemical properties into the same molecule. Peptides may contain reactive side chains, hydrophobic domains, cationic cell-penetrating sequences, oxidation-sensitive residues, or aggregation-prone motifs. Oligonucleotides may carry phosphorothioate backbones, 2'-modified sugars, morpholino chemistry, peptide nucleic acid backbones, terminal amines, thiols, azides, alkynes, fluorophores, or other functional groups. A linker that works well for one conjugate may reduce yield, complicate purification, or interfere with function in another.
This guide explains how to approach linker choice for custom peptide-oligonucleotide conjugates from a practical design perspective. It focuses on the questions researchers and procurement teams should resolve before ordering: whether the linker should be stable or cleavable, whether a spacer is needed, how hydrophilicity affects purification, where the peptide and oligonucleotide should be attached, and what analytical documentation should be requested.
In a peptide-oligonucleotide conjugate, the linker is not simply a passive bridge. It defines the chemical route used to join the peptide and nucleic acid, influences how the two domains orient relative to one another, and can change how the molecule behaves during purification and application. A well-matched linker supports a clean synthetic route and preserves the intended biological function. A poorly matched linker can generate heterogeneous products, low recovery, broad HPLC peaks, instability during storage, or ambiguous assay results.
The best linker is therefore application-specific. A diagnostic immobilization probe may need a stable spacer that keeps the recognition sequence away from a surface. A cell-penetrating peptide conjugate may need a hydrophilic spacer to reduce aggregation. A receptor-targeted conjugate may require distance between the ligand peptide and oligonucleotide cargo so that receptor binding is not sterically blocked. A reducible delivery conjugate may use a disulfide linker to release the oligonucleotide after cellular internalization, but that same linker may be unsuitable for applications requiring high extracellular stability.
Conjugation efficiency depends on whether the peptide and oligonucleotide carry compatible, accessible, and selective reactive handles. For example, thiol-maleimide conjugation usually requires a free thiol on one component and a maleimide on the other. Azide-alkyne click conjugation requires azide and alkyne handles. Amide formation requires an amine and an activated carboxyl group or related coupling strategy. If the chosen chemistry is not orthogonal to other functional groups in the peptide or oligonucleotide, side reactions may occur.
Peptide sequence also matters. A peptide containing multiple lysines, an N-terminal amine, and a cysteine may present several possible reaction sites unless the synthetic design controls which group is available for conjugation. Similarly, oligonucleotides may need a defined 5' or 3' modification to avoid a mixture of attachment positions. A linker design that looks simple on paper may become difficult if the reactive handle is sterically shielded, oxidized, hydrolyzed, or incompatible with the purification conditions.
Peptide-oligonucleotide conjugates often combine a highly charged oligonucleotide with a peptide that may be cationic, hydrophobic, amphipathic, or aggregation-prone. The linker can either improve or worsen this balance. Hydrophilic linkers such as PEG-type spacers can improve aqueous handling and reduce close contact between the peptide and oligonucleotide. Hydrophobic or bulky linkers may increase retention on reversed-phase HPLC, broaden peaks, or encourage self-association depending on the sequence.
Purification can be more complicated than purification of the peptide or oligonucleotide alone. The conjugate may have overlapping retention with unconjugated peptide, unconjugated oligonucleotide, oxidized peptide, hydrolyzed linker, or partially modified material. A linker that produces a clear mass shift and a distinct chromatographic profile is easier to purify and document. In some projects, the practical value of a linker is determined not only by its chemistry but also by whether the final product can be isolated at the requested purity and scale.
Biological performance depends on whether both domains remain functionally accessible. For a cell-penetrating peptide, the linker should not disrupt the distribution of cationic and hydrophobic residues that contribute to membrane interaction. For a receptor-binding peptide, the attachment site should avoid residues involved in receptor recognition. For an antisense or siRNA-related conjugate, the linker should not interfere with hybridization, nuclease resistance, strand loading, steric accessibility, or intracellular trafficking.
A very short linker may hold the peptide too close to the oligonucleotide, creating steric hindrance or electrostatic interaction between the two components. A very long flexible linker may improve accessibility but can also change hydrodynamic size, uptake behavior, or assay background. The goal is not always to maximize distance. The goal is to create enough separation for the intended function while maintaining chemical stability, manageable purification, and a well-defined molecular structure.
Before selecting a linker, researchers should define the intended role of the conjugate. Is the peptide used for cell penetration, receptor targeting, endosomal escape, immobilization, affinity capture, imaging, or assay readout? Is the oligonucleotide an antisense oligonucleotide, PMO, PNA, siRNA strand, aptamer, probe, or other nucleic acid format? Will the conjugate be used in buffer, serum-containing media, cell culture, tissue studies, or surface-based assays? These choices determine which linker characteristics matter most.
A stable linker is preferred when the peptide and oligonucleotide must remain connected throughout the experiment. This is common for diagnostic probes, immobilization constructs, hybridization assays, affinity capture systems, and many receptor-targeted conjugates where the peptide directs localization or binding. Stable linkers such as amide, triazole, or well-controlled thioether structures can support consistent interpretation because the conjugate remains intact under the intended conditions.
A cleavable linker is useful when the peptide is intended to assist delivery but the oligonucleotide should be released after reaching a specific environment. Disulfide linkers are often considered for reduction-sensitive release because intracellular reducing conditions may promote cleavage. Other cleavable designs may respond to enzymes, pH, or other triggers, although each requires careful feasibility assessment. Cleavable linkers can improve functional release, but they also introduce stability questions during synthesis, purification, storage, and handling.
The practical decision is based on where cleavage should occur and where it must not occur. If premature cleavage would invalidate the experiment, a stable linker may be safer. If permanent attachment reduces oligonucleotide activity, a cleavable linker may be worth evaluating. For early feasibility work, comparing a stable version and a cleavable version can help separate delivery effects from release effects.
Short linkers are compact and minimize added molecular weight. They can be suitable when steric hindrance is not expected, when the attachment site is far from the functional region, or when the conjugate must remain as small as possible. However, short linkers may cause the peptide and oligonucleotide to interact with each other or restrict access to a receptor, membrane, enzyme, surface, or complementary strand.
Spacer-containing linkers introduce distance and flexibility. PEG units, aminohexanoic acid-type spacers, glycine-serine motifs, or other hydrophilic spacers can help separate the peptide from the oligonucleotide. This can be important for receptor-targeting peptides, surface-immobilized probes, and conjugates where the peptide must remain accessible to a biological target. Spacer length should be selected deliberately rather than added automatically. Too little spacing may block function, while excessive spacing may complicate purification or alter biodistribution in biological experiments.
Hydrophilicity is a major design factor because peptide-oligonucleotide conjugates often challenge standard purification workflows. Hydrophilic linkers can improve aqueous solubility, reduce aggregation, and help balance hydrophobic peptide motifs. PEG-based linkers are frequently considered for this reason. Hydrophilic spacers may also reduce nonspecific surface adsorption in some assay formats.
Hydrophobic linkers may be acceptable or even useful in specific designs, but they increase the risk of poor solubility when combined with hydrophobic peptides or neutral oligonucleotide analogs. Bulky hydrophobic click handles, aromatic groups, or long alkyl spacers may shift HPLC behavior and affect how the conjugate partitions in biological systems. When the peptide is already hydrophobic, amphipathic, or rich in nonpolar residues, hydrophilic spacer design is often a practical way to reduce handling problems.
Peptide attachment can occur at the N-terminus, C-terminus, or a selected side chain. Terminal attachment is often straightforward because it can be designed during solid-phase peptide synthesis and may avoid modifying internal residues that contribute to biological activity. N-terminal attachment can be useful when the C-terminus must remain amidated or biologically active. C-terminal attachment may be preferred when the N-terminus is required for receptor binding, cell penetration, or enzymatic recognition.
Side-chain attachment provides site-specific control when terminal positions are functionally important. A cysteine thiol, lysine side-chain amine, glutamate or aspartate carboxyl group, or an unnatural amino acid bearing azide, alkyne, or other orthogonal functionality may be introduced at a defined position. Side-chain attachment is powerful but requires careful sequence review. Native cysteines may form disulfides, lysine-rich peptides may generate site heterogeneity if not protected correctly, and reactive residues near the pharmacophore may reduce activity.
Oligonucleotide attachment site should be selected according to the oligonucleotide type and mechanism. For antisense oligonucleotides, 5' or 3' conjugation may be feasible depending on the chemistry and target-binding requirements. For siRNA-related constructs, the sense strand, antisense strand, 5' end, and 3' end cannot be treated as interchangeable because strand loading and silencing activity may be sensitive to terminal modification. For probes and immobilization formats, the attachment site should preserve hybridization accessibility and orientation.
The oligonucleotide supplier or conjugation team should know whether the oligonucleotide will be delivered with a 5' amine, 3' amine, thiol, azide, alkyne, DBCO, maleimide, biotin, or another functional handle. The handle should be compatible with the peptide modification and stable under shipping and storage conditions. If the oligonucleotide is supplied as a protected disulfide or other latent handle, deprotection conditions should be considered before conjugation.
Several linker chemistries are commonly used in peptide-oligonucleotide conjugation. No single method is universally best. The choice depends on available handles, sequence compatibility, desired stability, purification constraints, and application requirements. The following strategies are often considered during feasibility review.
Thiol-maleimide chemistry is widely used because cysteine can be introduced into peptides at a defined position and maleimide-modified oligonucleotides are accessible through custom modification. The reaction can be efficient under mild aqueous conditions when the thiol is reduced and available. This makes it attractive for site-specific conjugation, especially when a single cysteine is intentionally placed at the peptide terminus or at a non-critical side-chain position.
The main concerns are thiol oxidation, competing thiols, and thioether stability under certain biological conditions. Free cysteine residues can form disulfides before conjugation if not handled properly. Maleimide groups can hydrolyze or participate in exchange reactions depending on conditions and time. For conjugates intended for serum-containing or intracellular studies, the stability profile should be discussed before selecting this linker as the default option.
Azide-alkyne click chemistry is valued for bioorthogonality and defined product formation. Copper-catalyzed azide-alkyne cycloaddition can generate a stable triazole linkage when one component carries an azide and the other carries a terminal alkyne. Strain-promoted azide-alkyne cycloaddition can avoid copper by using a strained alkyne such as DBCO, although bulky hydrophobic groups may influence solubility and purification.
Click strategies are useful when the peptide contains multiple natural functional groups that would complicate amine- or thiol-based chemistry. They are also attractive for research teams that want a stable non-cleavable linker with strong site-specific control. Practical considerations include the cost and availability of modified oligonucleotides, removal of catalyst or small-molecule reagents when used, and chromatographic separation of the conjugate from unreacted components.
Amide linkages are chemically stable and familiar in peptide chemistry. They can be formed by coupling an amine with an activated carboxyl group or by using related activated ester strategies. For conjugate design, amide linkers are attractive when long-term stability is required and when the reactive groups can be controlled precisely.
The main risk is lack of selectivity if multiple amines or carboxylates are present. Peptides commonly contain an N-terminal amine, lysine side chains, aspartate, and glutamate residues. Without protecting-group strategy or site-specific handle placement, amide formation can generate heterogeneous products. Amide linkers are therefore best used when the peptide design defines a single intended coupling site or when the chemistry is built into the peptide during synthesis.
Disulfide linkers are selected when reduction-sensitive cleavage is part of the design. They can be useful in delivery studies where the peptide assists cellular entry or targeting and the oligonucleotide is expected to be released in a more reducing intracellular environment. This can be relevant for some cell-penetrating peptide conjugates, receptor-mediated uptake studies, and exploratory intracellular release designs.
The trade-off is that disulfides are not universally stable. They may undergo reduction, exchange, or scrambling depending on buffer composition, thiol-containing additives, biological matrices, and storage conditions. Peptides containing native cysteines require special attention because unintended disulfide formation can produce mixtures. For disulfide-linked conjugates, analytical confirmation before and after handling may be important to ensure the test article remains suitable for the intended experiment.
PEG and other hydrophilic spacers are often used to improve solubility, reduce steric interference, and separate the peptide domain from the oligonucleotide domain. Short PEG units can provide modest spacing without adding excessive length. Longer PEG spacers may be considered when receptor binding, surface display, or hybridization accessibility requires more distance.
Spacer design should be matched to the application rather than selected by habit. A short hydrophilic spacer may be enough for many peptide-oligonucleotide conjugates. A longer spacer may be helpful when the peptide is a receptor ligand or when the oligonucleotide must hybridize efficiently near a surface. Excessive spacer length may change HPLC retention, broaden product distribution if the spacer is polydisperse, increase analytical complexity, or affect biological behavior.
| Linker Type | Required Handles | Main Advantage | Main Risk | Suitable Use |
| Thiol-maleimide | Cysteine or thiol on one component; maleimide on the other | Efficient site-specific conjugation under mild conditions | Thiol oxidation, maleimide hydrolysis, or exchange under some conditions | Research conjugates requiring defined cysteine-based attachment |
| Azide-alkyne click | Azide and terminal alkyne, or azide and strained alkyne | Bioorthogonal reaction with stable triazole formation | Catalyst removal for CuAAC or added hydrophobicity with bulky strained alkynes | Stable conjugates requiring strong site specificity |
| Amide | Amine and activated carboxyl group, or equivalent coupling design | Stable linkage with familiar synthetic chemistry | Possible heterogeneity when multiple amines or carboxylates are present | Designs with a single controlled coupling site |
| Disulfide | Compatible thiol or activated disulfide groups | Potential reduction-sensitive release | Premature cleavage, exchange, or scrambling in thiol-containing environments | Exploratory intracellular release and delivery studies |
| PEG or hydrophilic spacer | Spacer incorporated into peptide, oligonucleotide, or linker handle | Improved separation, flexibility, and aqueous handling | Excessive length may complicate purification or alter biological behavior | Receptor-targeted conjugates, surface probes, and aggregation-prone designs |
Table 1 Linker Strategy Comparison for Peptide-Oligonucleotide Conjugates
Linker selection becomes clearer when it is matched to the final use of the conjugate. The same peptide and oligonucleotide may require different linker designs for cell uptake, receptor targeting, hybridization assays, or immobilization. Application context should therefore be part of the initial quotation and feasibility discussion, not an afterthought after the sequences have already been fixed.
Cell-penetrating peptide conjugates are often designed to improve uptake of antisense oligonucleotides, splice-switching oligonucleotides, PMOs, PNAs, siRNA-related constructs, or other nucleic acid cargos. These peptides may be cationic, amphipathic, arginine-rich, lysine-rich, or sequence-optimized for membrane interaction. Because these motifs can interact strongly with the anionic oligonucleotide backbone, linker length and hydrophilicity can strongly influence aggregation and functional availability.
For many cell-penetrating peptide conjugates, a spacer can help reduce intramolecular association between the peptide and oligonucleotide. Stable linkers may be used when permanent attachment does not interfere with activity. Cleavable linkers may be explored when intracellular release is expected to improve function. The design should also consider the oligonucleotide chemistry. A phosphorothioate ASO, neutral PMO, PNA, or siRNA duplex may behave very differently after conjugation to the same peptide.
Receptor-targeted conjugates use a peptide ligand to guide the oligonucleotide toward a cell type or uptake pathway. In this setting, the linker must protect receptor recognition. If the attachment point is too close to the receptor-binding residues, affinity may be reduced. If the oligonucleotide is positioned too close to the ligand, the large nucleic acid domain may sterically interfere with binding.
Hydrophilic spacer-containing linkers are often considered for receptor-targeted designs because they can separate the ligand peptide from the oligonucleotide cargo. The peptide attachment site should be selected based on known or predicted structure-activity relationships. When the receptor-binding motif is uncertain, it may be useful to compare N-terminal, C-terminal, or side-chain attachment variants. Stable linkers are typically preferred when the peptide must remain connected during receptor engagement and trafficking, while cleavable designs require stronger justification and stability assessment.
Antisense oligonucleotides, phosphorodiamidate morpholino oligomers, peptide nucleic acids, and siRNA-related constructs place different constraints on linker design. ASOs may tolerate terminal conjugation depending on chemistry and mechanism, but the terminal modification should not compromise target binding or protein interactions required for activity. PMOs and PNAs are often neutral or less charged than standard nucleic acids, so peptide hydrophobicity and aggregation risk may become more prominent. siRNA designs require special attention to strand selection, duplex formation, and terminal compatibility.
For single-stranded antisense-type molecules, 5' or 3' attachment can often be evaluated based on the intended mechanism and existing structure-function information. For siRNA-related conjugates, attachment to the sense strand is often considered to reduce disruption of guide-strand function, but the exact design depends on the sequence, chemical modifications, and intended biological pathway. In all cases, the linker should be reviewed together with the oligonucleotide format rather than selected independently.
Diagnostic probes, capture probes, and immobilized assay reagents usually prioritize stability, orientation, and reproducibility. The linker should keep the recognition region accessible and reduce nonspecific interactions with the surface. Spacer-containing designs can be valuable when the oligonucleotide must hybridize near a solid support or when the peptide must bind a target after immobilization.
For immobilization applications, the attachment site and linker length can affect assay signal more than the intrinsic affinity of the recognition sequence. A probe that performs poorly may not have a weak sequence; it may simply be positioned too close to the surface or oriented unfavorably. Stable linkers and hydrophilic spacers are therefore common starting points for diagnostic and surface-display designs.
A successful custom conjugation project starts with complete design information. Peptide-oligonucleotide conjugates are highly project-specific, and small design details can determine whether the final molecule is feasible, purifiable, and fit for the intended assay. Before requesting synthesis, researchers should prepare information about the peptide, oligonucleotide, desired linker behavior, scale, purity, and analytical documentation.
The peptide sequence should be provided with all terminal modifications, side-chain modifications, stereochemistry, non-natural amino acids, cyclization requirements, protecting-group considerations, and known functional residues. If the conjugation site is already known, it should be specified clearly. If the site is uncertain, the supplier should be asked to evaluate whether N-terminal, C-terminal, cysteine-based, lysine-based, or unnatural amino acid-based attachment is most practical.
Sequence review is particularly important for peptides containing cysteine, methionine, tryptophan, multiple lysines, acidic clusters, hydrophobic segments, or highly cationic cell-penetrating motifs. These features can affect synthesis, oxidation, solubility, and purification. If the peptide has a known binding motif, membrane-active region, or enzymatic recognition sequence, that information should be shared so that the linker does not disrupt the functional site.
The oligonucleotide should be described by sequence, length, backbone chemistry, sugar modifications, terminal modifications, strand identity, and functional handle. For siRNA-related designs, it is important to state whether the peptide will be attached to the sense strand, antisense strand, 5' end, or 3' end. For PMO, PNA, ASO, aptamer, or probe designs, the attachment position should be selected based on hybridization, mechanism, and available modification chemistry.
If the oligonucleotide is supplied by another vendor, the exact handle and format should be confirmed before peptide synthesis is finalized. A nominal description such as "amine-modified oligo" may not be enough. The design team should know whether the amine is 5' or 3', whether it includes a spacer, whether it is supplied as a salt, whether purification has already been performed, and whether the material contains reducing agents, stabilizers, or counterions that may affect conjugation.
The intended stability profile should be defined in practical terms. Researchers should specify whether the conjugate needs to remain intact during storage, lyophilization, reconstitution, HPLC purification, cell culture, serum exposure, hybridization, receptor binding, intracellular trafficking, or surface immobilization. If cleavage is desired, the expected trigger and use environment should be described.
Stability requirements influence the choice between amide, triazole, thioether, disulfide, and other linker designs. They also influence storage recommendations and analytical release testing. A linker that is acceptable for short-term in vitro screening may not be suitable for long incubations in complex biological media. Conversely, a highly stable linker may not be ideal when intracellular release is necessary for activity.
Peptide-oligonucleotide conjugates should be ordered with realistic expectations for scale and purity. Final isolated yield depends on peptide synthesis, oligonucleotide modification quality, conjugation efficiency, purification recovery, and product stability. A small analytical feasibility batch may be appropriate before committing to a larger preparation, especially for difficult sequences or novel linker designs.
Analytical documentation should normally include identity confirmation and purity assessment using methods appropriate for the conjugate. HPLC or UPLC can support purity evaluation, while mass spectrometry can help confirm molecular weight. Depending on the oligonucleotide type and size, additional analytical approaches may be required. Researchers should state whether they need crude material, desalted material, HPLC-purified product, lyophilized product, concentration information, chromatograms, mass spectra, or other project-specific documentation.
| Design Question | Why It Matters | Information to Provide |
| What is the peptide sequence and functional region? | Avoids placing the linker where it may disrupt binding, uptake, or activity. | Full sequence, terminal modifications, non-natural residues, known active motif, preferred attachment site. |
| What oligonucleotide type is being conjugated? | ASO, PMO, PNA, siRNA, aptamer, and probe formats have different attachment constraints. | Sequence or oligo type, backbone chemistry, strand identity, 5' or 3' modification, existing handle. |
| Should the linker be stable or cleavable? | Determines whether the conjugate remains intact or releases the oligonucleotide under selected conditions. | Intended application, exposure conditions, desired release trigger, storage and handling requirements. |
| Is a spacer needed? | Controls steric separation, receptor accessibility, hybridization access, and surface presentation. | Need for short, PEG-type, hydrophilic, flexible, or application-specific spacer design. |
| What purity and documentation are required? | Aligns synthesis and purification strategy with downstream assay expectations. | Target scale, purity requirement, acceptable counterion or salt form, HPLC/UPLC and MS documentation needs. |
Table 2 Linker Design Checklist Before Ordering
A cationic cell-penetrating peptide attached directly to a phosphorothioate antisense oligonucleotide may show strong intramolecular association or aggregation. In such a case, adding a hydrophilic spacer and choosing a defined terminal attachment site may improve handling. A receptor-targeting peptide attached through a residue involved in receptor recognition may lose binding, even if conjugation is chemically successful. In that case, the linker problem is not yield but biological design.
A disulfide-linked conjugate may appear attractive for intracellular release, but the project team should consider whether reducing agents are present during purification, storage, or assay setup. A click-linked conjugate may be highly stable and site-specific, but bulky strained alkynes may add hydrophobic character. An amide-linked conjugate may be chemically robust, but only if the reactive site is controlled so that heterogeneous coupling does not occur.
These examples illustrate why linker selection should be reviewed before synthesis begins. The most efficient project workflow is usually not "make the peptide, make the oligo, then decide how to connect them." It is better to design the peptide modification, oligonucleotide handle, linker chemistry, purification strategy, and analytical plan as one integrated conjugation project.
Creative Peptides can support peptide-oligonucleotide conjugate projects from early design review through conjugation-ready peptide synthesis, linker selection, conjugation, purification, and analytical characterization. For projects involving custom peptide sequences, modified peptides, cell-penetrating peptides, receptor-targeting peptides, or linker-bearing peptide intermediates, sequence-level review helps identify suitable attachment sites and possible synthesis or solubility risks before the conjugation step.
The technical discussion can include whether the peptide should carry a cysteine, amine, azide, alkyne, maleimide-compatible handle, PEG spacer, hydrophilic spacer, or other project-specific modification. The oligonucleotide format can then be matched to the selected peptide handle and intended application. This integrated approach is useful when the customer has a defined peptide and oligonucleotide sequence but is unsure which linker chemistry, spacer length, or attachment site will be most practical.
Purification and analytical characterization are also central to project planning. Peptide-oligonucleotide conjugates may require method development to separate unconjugated peptide, unconjugated oligonucleotide, side products, and the desired conjugate. Analytical documentation can be aligned with the research use, target purity, and downstream assay needs. For difficult or novel designs, a feasibility review can help determine whether a pilot scale is appropriate before larger preparation.
To request a practical review of a custom peptide-oligonucleotide conjugate, researchers should provide the peptide sequence, oligonucleotide sequence or oligonucleotide type, preferred attachment site, existing or preferred linker chemistry, desired spacer length if known, target scale, purity requirement, and intended application. It is also helpful to provide information about storage conditions, assay buffer, cell type, delivery objective, receptor target, hybridization format, or immobilization platform if these are relevant.
If the linker has not yet been selected, the project can be reviewed based on design goals. For example, the request may state that the conjugate is intended for cell uptake screening, receptor-targeted ASO delivery, PMO delivery, PNA hybridization, siRNA-related evaluation, or surface immobilization. With that context, Creative Peptides can help evaluate whether a stable linker, cleavable linker, short linker, PEG spacer, terminal attachment, or side-chain attachment is more suitable for the research-use conjugate.
A clear project brief reduces redesign cycles and improves feasibility assessment. When the peptide sequence, oligonucleotide chemistry, linker preference, attachment site, scale, purity requirement, and application are provided at the beginning, the conjugation strategy can be evaluated as a complete molecular design rather than as separate peptide and oligonucleotide components.
Submit your peptide sequence, oligonucleotide sequence or type, preferred attachment site, linker preference, target scale, purity requirement, and intended application to discuss feasibility, design options, purification strategy, and analytical documentation for your custom peptide-oligonucleotide conjugate project.
There is no universal best linker. Stable amide or click linkers are often suitable when the peptide and oligonucleotide must remain connected, thiol-maleimide chemistry can be useful for defined cysteine-based attachment, and disulfide linkers may be considered when reduction-sensitive release is desired. The best choice depends on peptide sequence, oligonucleotide type, attachment site, stability requirement, purification behavior, and application.
Linker length affects steric separation, flexibility, solubility, receptor accessibility, hybridization access, and purification behavior. A short linker minimizes added mass but may cause steric hindrance. A spacer-containing linker, such as a PEG-type spacer, can improve accessibility and handling, but excessive length may complicate purification or alter biological performance.
Choose a non-cleavable linker when the peptide and oligonucleotide should remain connected during the experiment, such as in targeting, immobilization, or diagnostic probe applications. Choose a cleavable linker only when release of the oligonucleotide is part of the mechanism and the cleavage trigger is compatible with the intended biological environment.
Common conjugation handles include thiol, maleimide, amine, carboxyl, azide, alkyne, DBCO, activated ester, or activated disulfide groups. The peptide and oligonucleotide must carry compatible handles at defined attachment sites. The best handle combination depends on site specificity, sequence compatibility, and desired linker stability.
Yes. Linker chemistry can affect reaction efficiency, side-product formation, solubility, HPLC retention, peak shape, and separation from unconjugated peptide or oligonucleotide. Hydrophobic or bulky linkers may complicate purification, while hydrophilic spacers can sometimes improve handling. Final yield depends on synthesis, conjugation, purification recovery, and product stability.
